Wall Street analyst estimates for Enveric Biosciences, Inc. (ENVB): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 3 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 4 |
| Avg rating (1-5) | 0.75 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | |||
| 2026-08-14 | $-0.76 | ||
| 2026-05-15 | $-1.08 | ||
| 2026-03-27 | $0.85 | $-55.80 | +101.5% |
| 2025-11-14 | $-10.81 | $-63.00 | +82.8% |
| 2025-08-11 | $-11.64 | $-63.00 | +81.5% |
| 2025-05-13 | $-14.64 | $-72.00 | +79.7% |
| 2025-03-31 | $-57.96 | $-3.45 | -1580.0% |
Valuation Ratios
| Price / Book | 0.74 |
| EV / EBITDA | 0.87 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.1M | $48.6M | $43.0M | $39.9M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $29.6M | $38.4M | $34.0M | $31.8M | $120872 | $681612 | $435201 | $408030 | $337489 | $200858 |
| Gross Profit | $6.5M | $10.2M | $9.0M | $8.2M | -$120872 | -$681612 | -$435201 | -$408030 | -$337489 | -$200858 |
| Research & Development | 0 | 0 | 0 | 0 | $174083 | $4.8M | $8.0M | $7.3M | $2.8M | $2.8M |
| Selling, General & Admin | $9.0M | $18.5M | $10.8M | $12.2M | $5.3M | $20.5M | $11.5M | $8.8M | $6.5M | $5.8M |
| Operating Expenses | $10.3M | $21.7M | $13.7M | $14.5M | $5.5M | $25.3M | $19.5M | $16.0M | $9.3M | $8.6M |
| Operating Income | -$5.4M | -$12.0M | -$7.1M | -$6.3M | -$5.6M | -$25.9M | -$20.0M | -$16.4M | -$9.6M | -$8.8M |
| EBITDA | -$4.4M | -$7.7M | -$6.9M | -$2.3M | -$6.3M | -$55.7M | -$19.5M | -$16.9M | -$9.2M | -$8.6M |
| Interest Expense | $751074 | $575039 | $729896 | $691138 | $445250 | $10316 | $5249 | $3708 | 0 | $106 |
| Pre-tax Income | -$6.5M | -$11.5M | -$10.5M | -$5.2M | -$6.9M | -$56.4M | -$20.0M | -$17.3M | -$9.6M | -$8.8M |
| Income Tax | -$3.7M | -$2.4M | $6.3M | $388657 | 0 | -$7.5M | -$1.5M | $28913 | $8930 | $3.4M |
| Net Income | -$2.8M | -$9.1M | -$16.9M | -$5.6M | -$6.9M | -$49.0M | -$18.5M | -$17292 | -$9.6M | -$12.1M |
| EPS | $-12770.04 | $-36347.76 | $-42616.68 | $-2543.88 | $-666.00 | $-1244.28 | $-156.00 | $-97.08 | $-228.48 | $-36.24 |
| EPS (Diluted) | $-12770.04 | $-36347.76 | $-42616.68 | $-2543.88 | $-666.00 | $-1244.28 | $-156.00 | $-97.08 | $-228.48 | $-36.24 |
| Shares Outstanding (Diluted) | $218 | $250 | $396 | $2203 | $9589 | $39362 | $173189 | $179922 | $41908 | $334719 |
Price
| Price | $1.49 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Related companies: AZTR · HEPA · INDP · JSPR · ONCO · SCNI · SLRX
Explore sector: Healthcare · Biotechnology
More sections of ENVB: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks